- Previous Close
104.53 - Open
102.53 - Bid 105.10 x --
- Ask 107.40 x --
- Day's Range
102.53 - 107.40 - 52 Week Range
76.30 - 157.90 - Volume
115 - Avg. Volume
9,258 - Market Cap (intraday)
1.693B - Beta (5Y Monthly) 0.43
- PE Ratio (TTM)
21.84 - EPS (TTM)
4.87 - Earnings Date May 26, 2025 - May 30, 2025
- Forward Dividend & Yield 1.20 (1.15%)
- Ex-Dividend Date Sep 18, 2024
- 1y Target Est
--
Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic preparations targeting conditions, such as prostate enlargement, renal calculi, male infertility, and women health, etc. under the Stonex, Ashwamed, Prostowin, Suswas, Menoleap, and Ayursulin brands; anti-hypertensive, anti-lipidemic, and anti-obese products; skin care and bone health products; and cardiac care products under the Secremet and Servace brands. In addition, the company offers a range of APIs for therapeutic areas, such as anti-histamine, platelet inhibitor, anti-diabetic, anti-convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, and acne treatment, etc.; and various formulations, including tablets, capsules, syrups, suspensions, ophthalmic, creams, and ointments. Further, it engages in the treatment of gastrointestinal disorders; and piles, fistula, and constipation. The company exports its products to approximately 30 countries. Bal Pharma Limited was incorporated in 1987 and is based in Bengaluru, India.
www.balpharma.com868
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: BALPHARMA.BO
View MorePerformance Overview: BALPHARMA.BO
Trailing total returns as of 4/21/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BALPHARMA.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BALPHARMA.BO
View MoreValuation Measures
Market Cap
1.66B
Enterprise Value
2.95B
Trailing P/E
21.46
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.54
Price/Book (mrq)
2.42
Enterprise Value/Revenue
0.97
Enterprise Value/EBITDA
9.02
Financial Highlights
Profitability and Income Statement
Profit Margin
2.36%
Return on Assets (ttm)
4.20%
Return on Equity (ttm)
11.64%
Revenue (ttm)
3.24B
Net Income Avi to Common (ttm)
76.63M
Diluted EPS (ttm)
4.87
Balance Sheet and Cash Flow
Total Cash (mrq)
247.15M
Total Debt/Equity (mrq)
228.36%
Levered Free Cash Flow (ttm)
5.43M